Cargando…

Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) is caused by DMD mutations leading to dystrophin loss. Full‐length Dp427 is the primary dystrophin isoform expressed in muscle and is also expressed in the central nervous system (CNS). Two shorter isoforms, Dp140 and Dp71, are highly expressed in the CN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chesshyre, Mary, Ridout, Deborah, Hashimoto, Yasumasa, Ookubo, Yoko, Torelli, Silvia, Maresh, Kate, Ricotti, Valeria, Abbott, Lianne, Gupta, Vandana Ayyar, Main, Marion, Ferrari, Giulia, Kowala, Anna, Lin, Yung‐Yao, Tedesco, Francesco Saverio, Scoto, Mariacristina, Baranello, Giovanni, Manzur, Adnan, Aoki, Yoshitsugu, Muntoni, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977977/ https://www.ncbi.nlm.nih.gov/pubmed/35083887 http://dx.doi.org/10.1002/jcsm.12914

Ejemplares similares

Growth pattern trajectories in boys with Duchenne muscular dystrophy
por: Stimpson, Georgia, et al.
Publicado: (2022)

Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy
por: Zambon, Alberto A., et al.
Publicado: (2022)

Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency
por: Maresh, Kate, et al.
Publicado: (2022)

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
por: Ayyar Gupta, Vandana, et al.
Publicado: (2023)

Development of a novel startle response task in Duchenne muscular dystrophy
por: Maresh, Kate, et al.
Publicado: (2022)

Lessons Learned From Translational Research in Neuromuscular Diseases: Impact on Study Design, Outcome Measures and Managing Expectation
por: Stimpson, Georgia, et al.
Publicado: (2021)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples
por: Sardone, Valentina, et al.
Publicado: (2018)

Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
por: Weststrate, Harriet, et al.
Publicado: (2022)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Generation of two genomic-integration-free DMD iPSC lines with mutations affecting all dystrophin isoforms and potentially amenable to exon-skipping
por: Ferrari, Giulia, et al.
Publicado: (2020)

Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2019)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies
por: Janghra, Narinder, et al.
Publicado: (2016)

Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophy
por: Meng, Jinhong, et al.
Publicado: (2022)

Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement
por: Ramsey, Danielle, et al.
Publicado: (2022)

mRNA in situ hybridization exhibits unbalanced nuclear/cytoplasmic dystrophin transcript repartition in Duchenne myogenic cells and skeletal muscle biopsies
por: Falzarano, Maria Sofia, et al.
Publicado: (2023)

Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy
por: Meng, Jinhong, et al.
Publicado: (2016)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
por: Catapano, Francesco, et al.
Publicado: (2016)

Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials
por: Silwal, Arpana, et al.
Publicado: (2020)

Exon Exchange Approach to Repair Duchenne Dystrophin Transcripts
por: Lorain, Stéphanie, et al.
Publicado: (2010)

Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
por: Naidoo, Michael, et al.
Publicado: (2019)

Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
por: Happi Mbakam, Cedric, et al.
Publicado: (2022)

Cardiac Manifestations of Myotonic Dystrophy in a Pediatric Cohort
por: Brunet Garcia, Laia, et al.
Publicado: (2022)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
por: Cirak, Sebahattin, et al.
Publicado: (2011)

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene
por: Hoffman, Eric P.
Publicado: (2020)

Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
por: Farrokhi, Vahid, et al.
Publicado: (2021)

A Duchenne Muscular Dystrophy Gene Hot Spot Mutation in Dystrophin-Deficient Cavalier King Charles Spaniels Is Amenable to Exon 51 Skipping
por: Walmsley, Gemma L., et al.
Publicado: (2010)

Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2019)

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
por: Servais, Laurent, et al.
Publicado: (2022)

Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation Location
por: Milic Rasic, V, et al.
Publicado: (2015)

Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
por: Duan, Dongsheng
Publicado: (2018)

Dystrophin quantification: Biological and translational research implications
por: Anthony, Karen, et al.
Publicado: (2014)

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
por: Muntoni, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vpm5luo5a6b81o8qn2cfpl5mr8